Abstract / Summary
The 2026 AHA/ACC/ESC/WHF Expert Consensus Document on the Second Universal Definition of Heart Failure marks an important recalibration of how heart failure is recognized, classified, and studied. The document retains the central insight of the 2021 First Universal Definition—that heart failure is a clinical syndrome supported by structural, functional, biomarker, or congestion evidence—but moves the field toward earlier detection, etiologic precision, and trajectory-based care. This is a comprehensive commentary on the latest updates from the Second Universal Definition of Heart Failure. Its most visible changes include reaffirmation of the stage A to D continuum, stronger emphasis on pre-heart failure, simplification of ejection-fraction phenotypes into clinically actionable groups, a universal classification of causes, and new language for improvement, remission, recovery, worsening heart failure, and decompensated heart failure. For laboratory medicine, the definition is especially relevant because of its emphasis on natriuretic peptides, cardiac troponins, urine albumin–creatinine ratio, and emerging artificial-intelligence electrocardiography. This commentary reviews the main changes in the second definition, highlights implications for heart failure with preserved ejection fraction, obesity, cardiometabolic disease, global implementation, and frameworks for integrated clinical and laboratory pathways.